-
公开(公告)号：US10799569B2
公开(公告)日：2020-10-13
申请号：US16552873
申请日：2019-08-27
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
2.发明申请NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS 审中-公开新型肽和组合用于免疫细胞癌（HCC）和其他癌症的免疫治疗公开(公告)号：US20160250307A1
公开(公告)日：2016-09-01
申请号：US14975952
申请日：2015-12-21
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sara Kutscher
IPC分类号： A61K39/00 , C12N15/115 , G01N33/68 , C07K16/18 , A61K35/17 , C12N5/0783
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C07K2317/70 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.
摘要翻译： 本发明涉及用于免疫治疗方法的肽，蛋白质，核酸和细胞。 特别地，本发明涉及癌症的免疫治疗。 本发明还涉及单独或与其它肿瘤相关肽组合的肿瘤相关T细胞肽表位，其可以例如用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分或刺激T细胞 离体转移入患者。 与主要组织相容性复合物（MHC）分子结合的肽或本身的肽也可以是抗体，可溶性T细胞受体和其他结合分子的靶标。 特别地，本发明涉及可以用于引发抗肿瘤免疫应答的疫苗组合物中的几种新型肽序列及其衍生自人类肿瘤细胞的HLA I类和II类分子的变体或作为制备药物的靶标 /免疫活性化合物和细胞。
-
公开(公告)号：US12097249B2
公开(公告)日：2024-09-24
申请号：US17581049
申请日：2022-01-21
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
CPC分类号： A61K39/0011 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/5748 , G01N33/6848 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2310/16 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11679147B2
公开(公告)日：2023-06-20
申请号：US17853344
申请日：2022-06-29
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K35/17 , A61K39/00 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10 , A61K35/12
CPC分类号： A61K39/00111 , A61K35/17 , A61K38/04 , A61K39/0011 , A61K51/1057 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , G01N33/6803 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO: 56), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US11058754B2
公开(公告)日：2021-07-13
申请号：US16915465
申请日：2020-06-29
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10532091B1
公开(公告)日：2020-01-14
申请号：US16507375
申请日：2019-07-10
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K39/395 , A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US12102670B2
公开(公告)日：2024-10-01
申请号：US17576067
申请日：2022-01-14
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68
CPC分类号： A61K39/0011 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/5748 , G01N33/6848 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2310/16 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US12070491B2
公开(公告)日：2024-08-27
申请号：US17502170
申请日：2021-10-15
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US11576956B2
公开(公告)日：2023-02-14
申请号：US17516304
申请日：2021-11-01
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K35/17 , A61K39/00 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10 , A61K35/12
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
10.发明授权公开(公告)号：US10155032B2
公开(公告)日：2018-12-18
申请号：US15638072
申请日：2017-06-29
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68
摘要： A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.031 秒)
